An ARF-Independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 interaction

Cancer Cell

Volumn 18, Issue 3, 2010, Pages 231-243

  Macias, Everardo ^a   Jin, Aiwen ^a   Deisenroth, Chad ^a   Bhat, Krishna ^b   Mao, Hua ^a   Lindström, Mikael S ^c   Zhang, Yanping ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CYSTEINE; MYC PROTEIN; PHENYLALANINE; PROTEIN MDM2; PROTEIN P53; PROTEIN RPL11; PROTEIN RPL5; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MDM2 PROTEIN, HUMAN; PROTEIN BINDING; RIBOSOMAL PROTEIN L11; RIBOSOMAL PROTEIN L5; ZINC FINGER PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; DNA DAMAGE; FEMALE; GENE MUTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; GENETICS; HUMAN; METABOLISM; ONCOGENE MYC; RIBOSOME; TRANSGENIC MOUSE;

MUS;

ANIMALS; DNA DAMAGE; GENES, MYC; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS C-MYC; RIBOSOMAL PROTEINS; RIBOSOMES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; ZINC FINGERS;

EID: 77956518791     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.08.007     Document Type: Article

References (57)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538.
2. Alitalo K., Koskinen P., Makela T.P., Saksela K., Sistonen L., Winqvist R. myc oncogenes: activation and amplification. Biochim. Biophys. Acta 1987, 907:1-32.
3. Allison A.C. Mechanisms of action of mycophenolate mofetil. Lupus 2005, 14(Suppl 1):s2-s8.
4. Ayrault O., Andrique L., Seite P. Involvement of the transcriptional factor E2F1 in the regulation of the rRNA promoter. Exp. Cell Res. 2006, 312:1185-1193.
5. Barkic M., Crnomarkovic S., Grabusic K., Bogetic I., Panic L., Tamarut S., Cokaric M., Jeric I., Vidak S., Volarevic S. The p53 tumor suppressor causes congenital malformations in Rpl24-deficient mice and promotes their survival. Mol. Cell. Biol. 2009, 29:2489-2504.
6. Bates R.R., Wortham J.S., Counts W.B., Dingman C.W., Gelboin H.V. Inhibition by actinomycin D of DNA synthesis and skin tumorigenesis induced by 7,12-dimethylbenz(a)anthracene. Cancer Res. 1968, 28:27-34.
7. Bhat K.P., Itahana K., Jin A., Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 2004, 23:2402-2412.
8. Boon K., Caron H.N., van Asperen R., Valentijn L., Hermus M.C., van Sluis P., Roobeek I., Weis I., Voute P.A., Schwab M., Versteeg R. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001, 20:1383-1393.
9. Bouvard V., Zaitchouk T., Vacher M., Duthu A., Canivet M., Choisy-Rossi C., Nieruchalski M., May E. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene 2000, 19:649-660.
10. Chen D., Zhang Z., Li M., Wang W., Li Y., Rayburn E.R., Hill D.L., Wang H., Zhang R. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 2007, 26:5029-5037.
11. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., Golub T.R. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. USA 2000, 97:3260-3265.
12. Corvi R., Savelyeva L., Amler L., Handgretinger R., Schwab M. Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line. Eur. J. Cancer 1995, 31A:520-523.
13. Dai M.S., Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 2004, 279:44475-44482.
14. Dai M.S., Zeng S.X., Jin Y., Sun X.X., David L., Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 2004, 24:7654-7668.
15. Dai M.S., Jin Y., Gallegos J.R., Lu H. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia 2006, 8:630-644.
16. Dai M.S., Arnold H., Sun X.X., Sears R., Lu H. Inhibition of c-Myc activity by ribosomal protein L11. EMBO J. 2007, 26:3332-3345.
17. Dai M.S., Sun X.X., Lu H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol. Cell. Biol. 2008, 28:4365-4376.
18. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-MDM2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999, 13:2658-2669.
19. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
20. Flamm W.G., Banerjee M.R., Counts W.B. Topical application of actinomycin D on mouse skin: effect on the synthesis of ribonucleic acid and protein. Cancer Res. 1966, 26:1349-1360.
21. Fumagalli S., Di Cara A., Neb-Gulati A., Natt F., Schwemberger S., Hall J., Babcock G.F., Bernardi R., Pandolfi P.P., Thomas G. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat. Cell Biol. 2009, 11:501-508.
22. Gilkes D.M., Chen L., Chen J. MDMX regulation of p53 response to ribosomal stress. EMBO J. 2006, 25:5614-5625.
23. Herrera J.E., Savkur R., Olson M.O. The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res. 1995, 23:3974-3979.
24. Horn H.F., Vousden K.H. Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene 2008, 27:5774-5784.
25. Iapalucci-Espinoza S., Franze-Fernandez M.T. Effect of protein synthesis inhibitors and low concentrations of actinomycin D on ribosomal RNA synthesis. FEBS Lett. 1979, 107:281-284.
26. Itahana K., Bhat K.P., Jin A., Itahana Y., Hawke D., Kobayashi R., Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 2003, 12:1151-1164.
27. Jin A., Itahana K., O'Keefe K., Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 2004, 24:7669-7680.
28. Komarova E.A., Christov K., Faerman A.I., Gudkov A.V. Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene 2000, 19:3791-3798.
29. Lindstrom M.S., Jin A., Deisenroth C., White Wolf G., Zhang Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell. Biol. 2007, 27:1056-1068.
30. Ljungman M., Zhang F., Chen F., Rainbow A.J., McKay B.C. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 1999, 18:583-592.
31. Lohrum M.A., Ludwig R.L., Kubbutat M.H., Hanlon M., Vousden K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003, 3:577-587.
32. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
33. Menssen A., Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc. Natl. Acad. Sci. USA 2002, 99:6274-6279.
34. Muramatsu M., Hayashi Y., Onishi T., Sakai M., Takai K. Rapid isolation of nucleoli from detergent purified nuclei of various tumor and tissue culture cells. Exp. Cell Res. 1974, 88:245-251.
35. Ofir-Rosenfeld Y., Boggs K., Michael D., Kastan M.B., Oren M. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol. Cell 2008, 32:180-189.
36. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358:80-83.
37. Oliver E.R., Saunders T.L., Tarle S.A., Glaser T. Ribosomal protein L24 defect in belly spot and tail (Bst), a mouse Minute. Development 2004, 131:3907-3920.
38. Perry R.P. Balanced production of ribosomal proteins. Gene 2007, 401:1-3.
39. Perry R.P., Kelley D.E. Inhibition of RNA synthesis by actinomycin D: characteristic dose-response of different RNA species. J. Cell. Physiol. 1970, 76:127-139.
40. Picksley S.M., Lane D.P. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?. Bioessays 1993, 15:689-690.
41. Reifenberger G., Liu L., Ichimura K., Schmidt E.E., Collins V.P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993, 53:2736-2739.
42. Rubbi C.P., Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 2003, 22:6068-6077.
43. Ruggero D., Pandolfi P.P. Does the ribosome translate cancer?. Nat. Rev. Cancer 2003, 3:179-192.
44. Savkur R.S., Olson M.O. Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease. Nucleic Acids Res. 1998, 26:4508-4515.
45. Schlott T., Reimer S., Jahns A., Ohlenbusch A., Ruschenburg I., Nagel H., Droese M. Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumors. J. Pathol. 1997, 182:54-61.
46. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998, 12:2984-2991.
47. Sugimoto M., Kuo M.L., Roussel M.F., Sherr C.J. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 2003, 11:415-424.
48. Sun X.X., Dai M.S., Lu H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem. 2007, 282:8052-8059.
49. Sun X.X., Dai M.S., Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J. Biol. Chem. 2008, 283:12387-12392.
50. Tamborini E., Della Torre G., Lavarino C., Azzarelli A., Carpinelli P., Pierotti M.A., Pilotti S. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas. Int. J. Cancer 2001, 92:790-796.
51. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
52. Wanzel M., Russ A.C., Kleine-Kohlbrecher D., Colombo E., Pelicci P.G., Eilers M. A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with cell growth. Nat. Cell Biol. 2008, 10:1051-1061.
53. Yuan X., Zhou Y., Casanova E., Chai M., Kiss E., Grone H.J., Schutz G., Grummt I. Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol. Cell 2005, 19:77-87.
54. Zhang Y., Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009, 16:369-377.
55. Zhang Y., Wolf G.W., Bhat K., Jin A., Allio T., Burkhart W.A., Xiong Y. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 2003, 23:8902-8912.
56. Zhu Y., Poyurovsky M.V., Li Y., Biderman L., Stahl J., Jacq X., Prives C. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol. Cell 2009, 35:316-326.
57. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998, 12:2424-2433.